Molecular biomarkers for Alzheimer’s disease (AD) can support detection and improved care for patients, but novel candidates require verification. We previously reported a 12-micro RNA (miRNA) blood-based signature using next-generation sequencing (NGS) of 54 AD cases and 22 controls.
from Dementia Big http://ift.tt/1ncyy1A via alcoholic dementia
http://ift.tt/1P9HZtC
No comments:
Post a Comment